Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34(cdc2) kinase

Nature Medicine

Volumn 2, Issue 10, 1996, Pages 1140-1143

  Yao, Siu Long ^a   Akhtar, Adil J ^a   Mckenna, Karen A ^a   Bedi, Gauri C ^a   Sidransky, David ^a   Mabry, Mack ^a   Ravi, Rajani ^a   Collector, Michael I ^a   Jones, Richard J ^a   Sharkis, Saul J ^a   Fuchs, Ephraim J ^a   Bedi, Atul ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; PROTEIN KINASE; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL CYCLE; CONTROLLED STUDY; DNA DAMAGE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION INJURY; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; BONE MARROW; CAFFEINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CDC2 PROTEIN KINASE; DNA DAMAGE; ENZYME ACTIVATION; FEMALE; G2 PHASE; GENES, P53; MALE; MICE; MICE, KNOCKOUT; RADIATION TOLERANCE; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 16044371194     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1096-1140     Document Type: Article

References (29)

1. Thompson, C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462 (1995).
2. Steller, H. Mechanisms and genes of cellular suicide. Science 267, 1445-1449 (1995).
3. Fisher, D.E. Apoptosis in cancer therapy: Crossing the threshold. Cell 78, 539-542 (1994).
4. Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993).
5. Clark, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852 (1993).
6. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993).
7. Symonds, H. et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78, 703-711 (1994).
8. Lowe, S.W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
9. Kinzler, K.W. & Vogelstein, B. Clinical implications of basic research: Cancer therapy meets p53. N. Engl. J. Med. 331, 49-50 (1994).
10. Dulic, V. et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023 (1994).
11. El-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993).
12. Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V. & Kastan, M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89, 7491-7495 (1992).
13. Smith, M.L. et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266, 1376-1380 (1994).
14. Nurse, P. Universal control mechanism regulating onset of M-phase. Nature 344, 503-507 (1990).
15. Nurse, P. Ordering S phase and M phase in the cell cycle. Cell 79, 547-550 (1994).
16. Hartwell, L.H. & Weinert, T.A. Checkpoints: Controls that ensure the order of cell cycle events. Science 246, 629-634 (1989).
17. Murray, A.W. Creative blocks: Cell-cycle checkpoints and feedback controls. Nature 359, 599-604 (1992).
18. Lotem, J. & Sachs, L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82, 1092-1096 (1993).
19. Hunter, T. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 80, 225-236 (1995).
20. Lock, R.B., Galperina, O.V., Feldhoff, R.C. & Rhodes, L.J. Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res. 54, 4933-4939 (1994).
21. Michalovitz, D., Halevy, O. & Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62, 671-680 (1990).
22. Harbour, J.W. et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241, 353-357 (1988).
23. 2 delay. Cancer Res. 55, 1643-1648 (1995).
24. 1 checkpoint-competent cells. Cancer Res. 55, 1639-1642 (1995).
25. Fan, S. et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55, 1649-1654 (1995).
26. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
27. Bedi, A. et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition following DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 86, 1148-1158 (1995).
28. Th'ng, J.P.H. et al. The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene product. Cell 63, 313-324 (1990).
29. cdk2. Cancer Res. 54, 1412-1414 (1994).